IP Library Granted Patent US 8,361,753
Granted Patent B2
US 8,361,753 · App. 11/750,237 · Granted Jan 29, 2013

Phosphotriester-modified oligonucleotide primers for nucleic acid amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,361,753
App. No.
11/750,237
Granted
Jan 29, 2013
Kind
B2
Abstract

The present invention provides methods and compositions for nucleic acid amplification. These methods involve the use of oligonucleotide primers in temperature dependent nucleic acid amplification reactions. In certain aspects, the methods are accomplished by use of certain modified oligonucleotide primers which provide utility in nucleic acid amplification. In preferred embodiments, the oligonucleotide primers are modified with particular chemical groups such as esters.

Claims (125)

1. A method of amplifying nucleic acids, said method comprising:

amplifying nucleic acid using a modified oligonucleotide primer,

wherein said modified oligonucleotide primer comprises a modification group at one or two internucleotide linkages;

wherein said modification groups are at the n, n-1, n-2, or n-3 positions, wherein n is the 3′ terminal internucleotide linkage;

wherein the presence of said modification group impairs nucleic acid polymerase extension of said modified oligonucleotide primer;

wherein said modification group can be non-reversibly thermally dissociated; and

wherein said modified oligonucleotide primer has structure I as follows

wherein:

Nuc is a nucleoside within the primer sequence;

U and Z are independently O, S, Se, NR 9 , or CR 9 R 10 ;

R 9 and R 10 are each independently hydrogen or optionally substituted straight or branched hydrocarbyl having from 1-20 carbon atoms, wherein each may independently include at least one substituent selected from halo, oxo, hydroxyl, alkoxy, aryloxy, amino, amido or a detectable label;

Y is O, S or Se;

W is O, S, S(O), S(O) 2 , Se, C(O), C(S), C(O)NH, NH or NR 9 ; and

Q is a modification group comprising one or more thermally cleavable groups.

2. The method of claim 1 , wherein said modification group, Q, comprises one or more modification groups selected from the group consisting of

-L-X—R 1   (Formula I)

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms;

X is O, S, S(O), S(O) 2 , C(O), C(S) or C(O)NH; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl;

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy and heteroaryl;

-L-S(O) k —R 1   (Formula Ib)

wherein:

k is an integer from 0-2;

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl;

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

Each R 1 is independently hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl;

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl;

-L-R 2   (Formula II)

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 2 is hydrogen, cyano, or an optionally substituted carbocycle, heterocycle, aryl or heteroaryl having between

5-10 atoms;

-L a -A-L b -B  (Formula III)

wherein:

L a and L b are each independently selected from a bond or a straight or branched hydrocarbylene group having between 1-8 carbon atoms;

A is O, S, S(O), S(O) 2 , Se, CR 3 R 4 , NR 3 , C(O), C(S) or CNR 3 ;

B is C(O)R 3 , C(S)R 3 , C(O)NR 3 R 4 , OR 3 or SR 3 ; and

R 3 and R 4 are each independently hydrogen or straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl; and

-L a -D-L b -E-L c -F  (Formula IV)

wherein:

L a , L b and L c are each independently selected from a bond or a straight or branched hydrocarbylene group having between 1-8 carbon atoms;

D is O, S, S(O), S(O) 2 , CR 5 R 6 , and NR 5 ;

E is O, S, S(O), S(O) 2 , CR 5 R 6 , and NR 6 ;

F is hydrogen, C(O)R 7 , C(S)R 7 , C(O)NR 7 R 8 , OR 7 and SR 7 ;

R 5 and R 6 can each independently be hydrogen, aryl, alkyl, halo, oxo, hydroxyl, alkoxy, aryloxy or amino, or R 5 and R 6 can cooperate to form a mono or bicyclic ring consisting 5-10 atoms and including D, R 5 , R 6 , E and L b , provided that when R 5 and R 6 cooperate to form a ring, n is from 0-2; and

R 7 and R 8 are each independently selected from the group consisting of aryl, alkyl, halo, oxo, hydroxyl, alkoxy, aryloxy, amino, amido, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl.

3. The method of claim 1 , wherein said modification group, Q, comprises:

-L-X—R 1   (Formula I)

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms;

X is O, S, S(O), S(O) 2 , C(O), C(S) or C(O)NH; and

R′ is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

4. The method of claim 1 , wherein said modification group, Q, comprises:

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms;

and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

5. The method of claim 1 , wherein said modification group, Q, comprises:

-L-S(O) k —R 1   (Formula Ib)

wherein:

k is an integer from 0-2;

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms,

which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

6. The method of claim 1 , wherein said modification group, Q, comprises:

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

Each R 1 is independently hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

7. The method of claim 1 , wherein said modification group, Q, comprises:

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 1 is hydrogen or a straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

8. The method of claim 1 , wherein said modification group, Q, comprises:

-L-R 2   (Formula II)

wherein:

L is a straight or branched hydrocarbylene group having between 1-10 carbon atoms; and

R 2 is hydrogen, cyano, or an optionally substituted carbocycle, heterocycle, aryl or heteroaryl having between

5-10 atoms.

9. The method of claim 1 , wherein said modification group, Q, comprises:

-L a -A-L b -B  (Formula III)

wherein:

L a and L b are each independently a bond or a straight or branched hydrocarbylene group having between 1-8 carbon atoms;

A is O, S, S(O), S(O) 2 , Se, CR 3 R 4 , NR 3 , C(O), C(S) or CNR 3 ;

B is C(O)R 3 , C(S)R 3 , C(O)NR 3 R 4 , OR 3 or SR 3 ; and

R 3 and R 4 are each independently hydrogen or straight or branched hydrocarbylene group having from 1-20 carbon atoms, which may optionally include at least one substituent selected from the group consisting of hydrogen, aryl, alkyl, halo, oxo, hydroxyl, alkoxy, amino, amido, cycloalkyl, heterocycloalkyl, aryl, aryloxy, and heteroaryl.

10. The method of claim 1 , wherein said modification group, Q, comprises:

-L a -D-L b -E-L c -F  (Formula IV)

wherein:

L a , L b and L c are each independently selected from a bond or a straight or branched hydrocarbylene group having between 1-8 carbon atoms;

D is O, S, S(O), S(O) 2 , CR 5 R 6 , and NR 5 ;

E is O, S, S(O), S(O) 2 , CR 5 R 6 , and NR 6 ;

F is hydrogen, C(O)R 7 , C(S)R 7 , C(O)NR 7 R 8 , OR 7 and SR 7 ;

R 5 and R 6 can each independently be hydrogen, alkyl, aryl, halo, oxo, hydroxyl, alkoxy, aryloxy or amino, or R 5 and R 6 can cooperate to form a mono or bicyclic ring consisting 5-10 atoms and including D, R 5 , R 6 , E and L b , provided that when R 5 and R 6 cooperate to form a ring, n is from 0-2; and

R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, aryl, halo, oxo, hydroxyl, alkoxy, aryloxy, amino, amido, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl.

11. The method of claim 1 , wherein said modification group, Q, comprises one or more chemical moieties selected from the group consisting of 4-oxo-1-hexyl, 4-oxo-1-pentyl, 5-oxo-1-hexyl, 6-oxo-1-heptyl, 1-methyl-4-oxo-pentyl, 4-methylthio-1-butyl, 5-methyl-4-oxo-hexyl, 1-ethyl-4-oxo-pentyl, N-(2-hydroxyethyl)phthalimido, 2-(N-acetyl-N-methyl)aminoethyl, 2-(N-formyl-N-methyl)aminoethyl, 2-methyl-5-oxo-hexyl, 1,1-dimethyl-4-oxo-pentyl, 4-oxo-1-octyl, 4-oxo-1-tetradecyl, 4-oxo-1-eicosamyl, and 3-(N-tertbutylcarboxamido)-1-propyl.

12. The method according to claim 1 , wherein said modification group dissociates during the initial denaturation step of said amplification.

13. The method of claim 1 , wherein said modification group partially or entirely dissociates at a temperature between about 37° C.-95° C.

14. The method of claim 1 , wherein said modified oligonucleotide primer comprises a phosphotriester internucleotide linkage.

15. The method of claim 1 , wherein said modification group impairs hybridization of the oligonucleotide primer to a nucleic acid sequence.

16. The method of claim 1 , wherein t 1/2 of dissociation of said modification group is between about 0.1-120 minutes at 95° C.

17. The method of claim 1 , wherein the modification group dissociates between 50-95° C.

18. The method of claim 1 , wherein said nucleic acid amplification comprises a hot start polymerase.

19. The method of claim 1 wherein said modified oligonucleotide primer is at least 90% chirally pure.

20. The method of claim 1 , wherein said oligonucleotide primer comprises a detectable label.

21. The method of claim 1 , wherein said amplifying comprises polymerase chain reaction (PCR).

22. The method of claim 21 , wherein said PCR comprises multiplex PCR.

23. The method of claim 22 , wherein a first target comprises amplifying using unmodified primers and a second target is amplified using modified primers.

24. The method of claim 22 , wherein a first target comprises amplifying using one or more primers with a first modification group and a second target is amplified using one or more modified primers with a second modification group, wherein said first and second modification groups are different.

25. The method of claim 1 , wherein said amplifying comprises reverse transcriptase (RT).

26. The method of claim 25 , wherein said modification group dissociates at about 37-70° C.

27. The method of claim 25 , wherein said modification group dissociates at 42° C.

28. The method of claim 1 , wherein said amplifying comprises subsequent enzymatic reactions in a single tube.

29. The method of claim 28 , wherein said subsequent enzymatic reactions comprise reverse transcriptase (RT) as a first enzymatic reaction and polymerase chain reaction (PCR) as a second enzymatic reaction.

30. The method of claim 29 , wherein said RT reaction comprises amplifying with one or more unmodified primers and said PCR reaction comprises amplifying with one or more modified primers.

31. The method of claim 29 , wherein said RT reaction comprises amplifying with one or more of a first modified primer and said PCR reaction comprises amplifying with one or more of a second modified primer.

32. The method of claim 31 , wherein said one or more of a first modified primer comprises a modification group that dissociates at about 42° C., and wherein said one or more of a second modified primer comprises a modification group that dissociates at about 95° C.

33. The method of claim 1 , wherein said modified oligonucleotide primer comprises a modification group at the 3′ terminal internucleotide linkage.

34. The method of claim 33 , wherein said modified oligonucleotide primer further comprises a modification groups at the n-1 position; wherein n is the 3′ terminal internucleotide linkage.

Assignments (14)
SECURITY INTEREST Recorded Jun 3, 2026
From: TRILINK BIOTECHNOLOGIES, LLC; CYGNUS TECHNOLOGIES, LLC; GLEN RESEARCH, LLC
To: BSP AGENCY, LLC, AS COLLATERAL AGENT
Reel/Frame 074835/0788 →
CHANGE OF NAME Recorded Dec 14, 2022
From: TRILINK BIOTECHNOLOGIES, INCORPORATED
To: TRILINK BIOTECHNOLOGIES, LLC
Reel/Frame 062124/0819 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 022142 FRAME: 0111. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 27, 2022
From: ZON, GERALD; LEBEDEV, ALEXANDRE
To: TRILINK BIOTECHNOLOGIES, INCORPORATED
Reel/Frame 061553/0775 →
RELEASE OF SECOND LIEN SECURITY INTEREST Recorded Oct 19, 2020
From: ANTARES CAPITAL LP
To: VECTOR LABORATORIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH, LLC
Reel/Frame 054118/0763 →
SECURITY AGREEMENT Recorded Oct 19, 2020
From: MARAVAI LIFE SCIENCES, INC.; TRILINK BIOTECHNOLOGIES, LLC; VECTOR LABORATORIES, INC.; GLEN RESEARCH, LLC; CYGNUS TECHNOLOGIES, LLC; MOCKV SOLUTIONS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 054118/0848 →
RELEASE OF FIRST LIEN SECURITY INTEREST Recorded Oct 19, 2020
From: JPMORGAN CHASE BANK, N.A.
To: VECTOR LABORATORIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH, LLC
Reel/Frame 054118/0751 →
RELEASE AND REASSIGNMENT OF SECURITY INTEREST RECORDED AT REEL/FRAME 41277/0753 Recorded Sep 13, 2018
From: NXT CAPITAL, LLC
To: TRILINK BIOTECHNOLOGIES, LLC
Reel/Frame 047089/0675 →
SECURITY AGREEMENT Recorded Aug 3, 2018
From: TRILINK BIOTECHNOLOGIES; TRILINK BIOTECHNOLOGIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH CORPORATION
To: ANTARES CAPITAL LP, AS COLLATERAL AGENT
Reel/Frame 046702/0651 →
SECURITY AGREEMENT Recorded Aug 2, 2018
From: TRILINK BIOTECHNOLOGIES; TRILINK BIOTECHNOLOGIES, INC.; TRILINK BIOTECHNOLOGIES, LLC; GLEN RESEARCH CORPORATION
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 046708/0095 →
SECURITY INTEREST Recorded Feb 16, 2017
From: TRILINK BIOTECHNOLOGIES, LLC
To: NXT CAPITAL, LLC, AS AGENT
Reel/Frame 041277/0753 →
CONFIRMATORY LICENSE Recorded Apr 26, 2013
From: TRILINK TECHNOLOGIES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030295/0490 →
CONFIRMATORY LICENSE Recorded Apr 26, 2013
From: TRILINK BIOTECHNOLOGIES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030295/0502 →
CONFIRMATORY LICENSE Recorded Mar 29, 2012
From: TRILINK BIOTECHNOLOGIES, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027956/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2009
From: ZON, GERALD; LEBEDEV, ALEXANDRE
To: TRILINK BIOTECHNOLOGIES
Reel/Frame 022142/0111 →